Daiwa Securities Group
SYRE icon

Daiwa Securities Group’s Spyre Therapeutics SYRE Stock Holding History

Daiwa Securities Group’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-258
Closed -$8K – 1418
2025
Q4 		$8K Buy
258
+52
+25% +$1.36K ﹤0.01% 1201
2025
Q3 		$3K Hold
206
– – ﹤0.01% 1250
2025
Q2 		$3K Hold
206
– – ﹤0.01% 1199
2025
Q1 		$3K Buy
+206
New +$4.29K ﹤0.01% 1168
2022
Q4 		– Sell
-4
Closed – – 1383
2022
Q3 		$0 Hold
4
– – ﹤0.01% 1393
2022
Q2 		$0 Hold
4
– – ﹤0.01% 1424
2022
Q1 		$0 Hold
4
– – ﹤0.01% 1414
2021
Q4 		$0 Hold
4
– – ﹤0.01% 1441
2021
Q3 		$1K Hold
4
– – ﹤0.01% 1284
2021
Q2 		$1K Hold
4
– – ﹤0.01% 1214
2021
Q1 		$1K Hold
4
– – ﹤0.01% 1225
2020
Q4 		$1K Sell
4
-6
-60% -$1.24K ﹤0.01% 1204
2020
Q3 		$2K Buy
10
+4
+67% +$740 ﹤0.01% 1144
2020
Q2 		$1K Hold
6
– – ﹤0.01% 1195
2020
Q1 		$1K Hold
6
– – ﹤0.01% 1199
2019
Q4 		$1K Hold
6
– – ﹤0.01% 1190
2019
Q3 		$1K Hold
6
– – ﹤0.01% 1160
2019
Q2 		$1K Hold
6
– – ﹤0.01% 1186
2019
Q1 		$1K Buy
+6
New +$1.25K ﹤0.01% 1169

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Daiwa Securities Group's SYRE Position: Q1 2026 in Review

Daiwa Securities Group sold out of Spyre Therapeutics (SYRE) in Q1 2026, closing a stake of 258 shares — an estimated $8K sold.

Daiwa Securities Group first reported a position in SYRE in Q1 2019 and held it in 19 quarters. The position peaked at $8K in Q4 2025. 198 funds tracked by Wall St. Rank hold SYRE as of Q1 2026.

  • Daiwa Securities Group reported no remaining Spyre Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Daiwa Securities Group sold 258 Spyre Therapeutics shares in Q1 2026, an estimated $8K.
  • Daiwa Securities Group first reported a position in Spyre Therapeutics in Q1 2019 and held it in 19 quarters.
  • Daiwa Securities Group's Spyre Therapeutics position peaked at $8K in Q4 2025.
  • 198 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2026.

Based on Daiwa Securities Group's 13F filing for Q1 2026, filed 13 May 2026.